All News

The protection and privacy of healthcare data is a massive hurdle for the new technology to overcome.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses new real-world data showing that most high-risk cardiovascular patients in the US are not starting or intensifying lipid-lowering therapy—and few are achieving guideline-recommended LDL-C targets.

The campaign promotes women to have conversations with their family members about heart health history.

Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.

Groups like PhRMA and the HDA issued statements explaining their stance of the drug-pricing policy.

Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how repurposing GLP-1s and psychedelics for addiction treatment introduces unexpected patent challenges, liability concerns, and complex state-by-state regulatory hurdles.

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

The order pushes drug companies to reduce drug prices in the United States to fall in line with other countries around the world.

The President plans to sign an executive order on Monday morning to enforce the trade clause.

Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing $250 million to pharmaceutical innovation and workforce development through its extended partnership with Purdue University.

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how regulatory, patent, and reimbursement challenges are slowing venture investment in GLP-1 and psychedelic addiction therapies.

The provider hopes that this option will be a solution to the state’s primary care physician shortage.

The company shifted several key presidents to adjust its global priorities.

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis.

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following herniorrhaphy and bunionectomy surgeries compared to placebo.

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years.

The program will send 11 young soccer players to learn from professional soccer coaches in Madrid.

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs’ potential into new therapeutic areas.

The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving at least a 50% reduction in apnea-hypopnea index.

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when treated with bulevirtide maintained suppression for nearly two years.

The campaign provides information about early signs of the condition along with treatment information.

ConnectING with Carnie promotes the importance of routine screening and treatment options for the involuntary movement condition.

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.